CLEVELAND, Aug. 8 /PRNewswire-FirstCall/ -- Cleveland BioLabs, Inc. (NASDAQ:CBLI)(Boston Stock Exchange:CFB) announced today that from August 8-11, 2006, it will present detailed scientific results of its recently completed non-human primate study of its lead radioprotective drug candidate, Protectan CBLB502, during the poster presentation sessions at the 9th Annual Force Health Protection Conference in Albuquerque, New Mexico.

"We are pleased to report the results of the trials of our lead drug candidate, Protectan CBLB502, to the broad group of military, Veterans Administration and Department of Defense civilian professionals," said Michael Fonstein, Ph.D., President and Chief Executive Officer at Cleveland BioLabs.

About Cleveland BioLabs, Inc.

Cleveland BioLabs, Inc. is a drug discovery and development company with the goal to identify and develop new types of drugs for the protection of normal tissues from exposure to radiation and other stresses, such as toxic chemicals and for cancer treatment. Our development efforts are based on discoveries made in connection with the investigation of the cell-level process known as apoptosis. To learn more about Cleveland BioLabs Inc., please visit the company's website at

This press release contains forward-looking statements that reflect our current view with respect to various aspects of the events described above. Actual results could be significantly different. Factors that could affect results include those set forth in filings made by Cleveland BioLabs, Inc. with the Securities and Exchange Commission. These factors include, but are not limited to, those discussed in our Registration Statement on Form SB-2 under the caption "Risk Factors." We caution readers not to place undue reliance on these forward-looking statements. Although forward-looking statements help provide complete information about future prospects, readers should keep in mind that forward- looking statements are much less reliable than historical information.